Protalix BioTherapeutics (PLX) Cash from Discontinued Operations (2015 - 2017)
Protalix BioTherapeutics' quarterly Cash from Discontinued Operations came in at 2000.0 in Q3 2017, up 100.68% year-on-year from 996.63 in Q3 2016, and up 125.0% quarter-over-quarter from 8000.0 in Q2 2017.
Protalix BioTherapeutics has reported Cash from Discontinued Operations for 3 years, with the latest figure at 2000.0 in Q3 2017.
- For the quarter ending Q3 2017, Cash from Discontinued Operations rose 100.68% year-over-year to 2000.0; the trailing twelve-month figure through Sep 2017 stood at 116000.0 (down 97.19% YoY), and the FY2016 full-year result was 11000.0, down 100.74% from the prior year.
- Cash from Discontinued Operations for Q3 2017 stood at 2000.0, up from 8000.0 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 4138000.0 in Q4 2015, with the low at 1406000.0 in Q3 2015.
- Average Cash from Discontinued Operations over 3 years is 159100.0, with a median of 131000.0 recorded in 2015.
- Year-over-year, Cash from Discontinued Operations jumped 164.72% in 2016 and plunged 101.25% in 2017.
- Tracing PLX's Cash from Discontinued Operations over 3 years: stood at 4138000.0 in 2015, then tumbled by 107.15% to 296000.0 in 2016, then jumped by 100.68% to 2000.0 in 2017.
- The last three Cash from Discontinued Operations figures came in at 2000.0 (Q3 2017), 8000.0 (Q2 2017), and 122000.0 (Q1 2017), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 2,000.00 |
| Sep 30, 2017 | 2,000.00 |
| Jun 30, 2017 | -8,000.00 |
| Jun 30, 2017 | -8,000.00 |
| Mar 31, 2017 | 122,000.00 |
| Mar 31, 2017 | 122,000.00 |
| Sep 30, 2016 | -296,000.00 |
| Sep 30, 2016 | -296,000.00 |
| Jun 30, 2016 | 642,000.00 |
| Jun 30, 2016 | 642,000.00 |
| Mar 31, 2016 | -357,000.00 |
| Mar 31, 2016 | -357,000.00 |
| Dec 31, 2015 | 4.14 Mn |
| Dec 31, 2015 | 4.14 Mn |
| Sep 30, 2015 | -1.41 Mn |
| Sep 30, 2015 | -1.41 Mn |
| Jun 30, 2015 | -992,000.00 |
| Jun 30, 2015 | -992,000.00 |
| Mar 31, 2015 | -254,000.00 |
| Mar 31, 2015 | -254,000.00 |